Welcome to our dedicated page for Prestige Consmr Healthcare news (Ticker: PBH), a resource for investors and traders seeking the latest updates and insights on Prestige Consmr Healthcare stock.
Prestige Consumer Healthcare Inc (NYSE: PBH) maintains leadership in over-the-counter healthcare through trusted brands like Clear Eyes and Summer’s Eve. This news hub provides investors and industry professionals with essential updates on corporate developments, regulatory milestones, and market strategies.
Access comprehensive coverage of PBH’s operational updates including earnings announcements, product innovations, and supply chain initiatives. Our curated news collection offers context for understanding the company’s position in competitive OTC markets across North America and international regions.
Key updates feature strategic partnerships, quality assurance developments, and responses to evolving consumer health trends. The resource serves as a centralized reference for tracking PBH’s commitment to product stewardship and operational efficiency in dynamic healthcare markets.
Bookmark this page for streamlined access to press releases and analysis on PBH’s market navigation. Regular updates ensure stakeholders maintain current awareness of corporate initiatives impacting long-term value creation in consumer healthcare.
Prestige Consumer Healthcare (NYSE: PBH) reported its fiscal year 2024 results with $277.0 million in Q4 revenue and $1,125.4 million for the full year, a slight 0.2% increase from the previous year. Q4 net income was $49.5 million, a significant improvement from the previous year's net loss of $240.6 million. The company's leverage ratio was reduced to 2.8x, below its long-term target. The Board authorized a new $300 million share repurchase program. For fiscal 2025, Prestige anticipates a 1% organic revenue growth and an EPS range of $4.40 to $4.46. Ongoing supply chain issues, particularly in eye care products, affected Q4 performance but are expected to improve mid-2025.
